anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A medicine used for treating eczema, the nettle rash, and the itchy sickness and the usage relate to the traditional Chinese medicine domain. The present invention selects such traditional Chinese medicines as the American lopseed, ledeboruiella root, and dwarf lilyturf and so on by different component of dosage, with less variety of medicine and less complexity. The efficacy affects the coordination from the pathology, in the aspects of eliminating the stasis, dispelling wind-heat, removing Shi, disintoxicating, and nourishing Yin, which can double the result with half effort. The traditional Chinese medicines mentioned above are thickly fried together, being taken hot simultaneously. Meanwhile, a piece of cloth is used to wrap a red brick boiled with barmy hogwash. The brick is put under the foot with each arch a half. The patient snugly is covered with bedclothes to make perspiration, with treatment form the inside and outside of the body, which enables the sweat runs down like raindrops and soaks the bedding. Patient can recover from the illness with the perspiration. A set of medicine can be taken altogether two times. The patient snugly is covered with bedclothes to make perspiration in the daytime, and then the medicines are taken alone at night. The pills, powder and capsule are made through the extraction. The medicine is taken as the above direction, and Patient can recover from the illness in four days.
#### Pregnancy category C; Category D starting 30 weeks gestation. 

There are no adequate and well-controlled studies in pregnant women. Meloxicam crosses the placental barrier. Prior to 30 weeks gestation, use meloxicam during pregnancy only if the potential benefit justifies the potential risk to the fetus. Starting at 30 weeks gestation, avoid meloxicam and other NSAIDs, in pregnant women as premature closure of the ductus arteriosus in the fetus may occur. If this drug is used during this time period in pregnancy, inform the patient of the potential hazard to a fetus [see Warnings and Precautions (5.9) and Patient Counseling Information (17.8)]. 

### Teratogenic Effects 

Meloxicam was not teratogenic when administered to pregnant rats during fetal organogenesis at oral doses up to 4 mg/kg/day (2.6 fold greater than the maximum recommended human daily dose [MRHD] based on body surface area [BSA] comparison). Administration of meloxicam to pregnant rabbits throughout embryogenesis produced an increased incidence of septal defects of the heart at an oral dose of 60 mg/kg/day. The no effect level was 20 mg/kg/day (26 fold greater than the MRHD based on BSA conversion). 

### Nonteratogenic Effects 

In rats and rabbits, embryolethality occurred at oral meloxicam doses of 1 mg/kg/day and 5 mg/kg/day, respectively (0.65 and 6.5 fold greater, respectively, than the MRHD based on BSA comparison) when administered throughout organogenesis.
Participants with selected solid tumors will receive a selected dose of RO7515629 intravenously as a single agent based on the recommended dose sequence for expansion (RDE) and dosing regimen selected from Part I and Part II. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.
The study of pain mechanisms has advanced significantly with the development of innovative in vitro models. This chapter explores those already used in or potentially useful for neuropathic pain research, emphasizing the complementary roles of animal and human cellular models to enhance translational success. Traditional animal models have provided foundational insights into the neurobiology of pain and remain invaluable for understanding complex pain pathways. However, integrating human cellular models addresses the need for better replication of human nociceptors. The chapter details methodologies for culturing rodent and human primary sensory neurons, including isolation and culture techniques, advantages, and limitations. It highlights the application of these models in neuropathic pain research, such as identifying pain-associated receptors and ion channels. Recent advancements in using induced pluripotent stem cell (iPSC)-derived sensory neurons are also discussed. Finally, the chapter explores advanced in vitro models, including 2D co-cultures and 3D organoids, and their implications for studying neuropathic pain. These models offer significant advantages for drug screening and ethical research practices, providing a more accurate representation of human pain pathways and paving the way for innovative therapeutic strategies. Despite challenges such as limited access to viable human tissue and variability between samples, these in vitro models, alongside traditional animal models, are indispensable for advancing our understanding of neuropathic pain and developing effective treatments.
Little is known about the impacts of fatigue after cancer treatment, including whether cancer-related fatigue impacts people's use of healthcare. This study sought to examine how cancer-related fatigue impacts healthcare use after completing cancer treatment. A population-based survey was administered in Nova Scotia, Canada, to examine survivors' experiences and needs after completing cancer treatment. Respondents included survivors of breast, melanoma, colorectal, prostate, hematologic, and young adult cancers who were 1-3 years post-treatment. Survey responses were linked to cancer registry, physicians' claims, hospitalization, and ambulatory care data. Data were analyzed descriptively and using regression models. The final study cohort included 823 respondents. Younger respondents reported higher levels of cancer-related fatigue compared to older respondents. More females than males reported cancer-related fatigue. Upon adjusted analyses, those with cancer-related fatigue had lower odds of being discharged to primary care for their cancer-related follow-up (odds ratio = 0.71, p = 0.029). Moreover, those with cancer-related fatigue had 19% higher primary care use (incidence rate ratio = 1.19, p < 0.0001) and 37% higher oncology use (incidence rate ratio = 1.37, p < 0.016) during the follow-up period compared to those without cancer-related fatigue. Providers (oncology and primary care) may require additional support to identify clinically relevant fatigue and refer patients to appropriate resources and services.
BACKGROUND: In traditional Asian medicine, dried rhizomes of Ligusticum chuanxiong Hort. (Chuanxiong Rhizoma [CR]) have long been used to treat pain disorders that affect the head and face such as headaches. Furthermore, they have been used primarily for blood circulation improvement or as an analgesic and anti-inflammatory medicine. This study aimed to investigate the neuroprotective effects of a methanol extract of CR (CRex) on ischemic stroke in mice caused by middle cerebral artery occlusion (MCAO).
METHODS: C57BL/6 mice were given a 1.5-h transient MCAO (MCAO control and CRex groups); CRex was administered in the mice of the CRex group at 1,000-3,000 mg/kg either once (single dose) or twice (twice dose) before MCAO. The mechanism behind the neuroprotective effects of CRex was examined using the following techniques: brain infarction volume, edema, neurological deficit, novel object recognition test (NORT), forepaw grip strength, and immuno-fluorescence staining.
RESULTS: Pretreating the mice with CRex once at 1,000 or 3,000 mg/kg and twice at 1,000 mg/kg 1 h before MCAO, brought about a significantly decrease in the infarction volumes. Furthermore, pretreating mice with CRex once at 3,000 mg/kg 1 h before MCAO significantly suppressed the reduction of forepaw grip strength of MCAO-induced mice. In the MCAO-induced group, preadministration of CRex inhibited the reduction in the discrimination ratio brought on by MCAO in a similar manner. CRex exhibited these effects by suppressing the activation of astrocytes and microglia, which regulated the inflammatory response.
CONCLUSIONS: This study proposes a novel development for the treatment of ischemic stroke and provides evidence favoring the use of L. chuanxiong rhizomes against ischemic stroke.
The present invention relates to a medicine for treating kidney diseases and a preparation method. The medicine for treating kidney diseases is a medicament prepared from raw materials with the following weight proportion: 100 to 300 shares of boenninghausenia sessilicarpa, 75 to 225 shares of folium orthosiphoni, 50 to 150 shares of phellodendron bark, 50 to 150 shares of lalang grass rhizome, 50 to 150 shares of tuckahoe, 50 to 150 shares of largehead atractylodes rhizome, 25 to 75 shares of honeysuckle flower, 50 to 150 shares of milkvetch root, 50 to 150 shares of licorice root, 25 to 75 shares of common rush, 25 to 75 shares of common lophatherum herb and 50 to 150 shares of water plantain. When the present invention is used for treating kidney diseases (glomerular nephritis), according to the difference of pathogenetic conditions and the different stages of hormonotherapy, the western medicine is matched with the treatment of the traditional Chinese medicines, and accordingly, the medicine for curing kidney diseases can not only lighten hormone adverse reaction, but also increase treating effects. The medicine for curing kidney diseases can treat the symptoms, such as waist soreness, lumbodynia, dizziness and tinnitus, heat in the heart of the palms and soles, buccopharyngeal dryness, red tongues without fur, deep and thready pulse manifestation or wiry pulse manifestation, etc. The medicine for curing kidney diseases has outstanding treating effects on the symptoms, and accordingly, the secretion of adrenal cortex in vivo can be prompted, the withdrawal and reduction syndrome of hormone can be relieved, a rebound phenomenon caused by withdrawal can be reduced, and the treating effects are strengthened. The medicine of the present invention also has the action of antipyresis, inflammation, antisepsis and virus resistance.
The invention provides a skin-refreshing essence set which comprises an essence emulsion, and an essence solution No. 1, an essence solution No. 2, an essence solution No. 3 and an essence solution No. 4 which are sequentially used, wherein the essence emulsion comprises water, glycerol, 1, 3-propylene glycol, isosorbide dimethyl ether, dipropylene glycol, inositol, isoprene glycol, hydroxydecyl ubiquinone, cetyl ethyl hexanoate and other components, and the essence solution comprises water, 1, 3-propylene glycol, dipropylene glycol, lactic acid, 1, 2-pentanediol, crinkle carrageenan, butanediol, hydrolyzed royal jelly protein and other components. The skin refreshing essence set disclosed by the invention contains hydroxydecyl ubiquinone (idebene) and various skin beautifying and refreshing components, can effectively soften the horny layer, improve the skin absorption capacity and water content, supplement skin nutrients, strengthen and toughen the skin, endow the skin with elastic and compact feeling, and enable the skin to be smooth, fine, fresh and bright; the skin repairing cream has the advantages of repairing skin problems, improving various skin troubles such as coarse pores, roughness, dullness and the like, and rejuvenating young and plump skin.
Participants with BCC lesions were administered to PDT with Placebo cream applied topically for three hours, followed by illumination using noncoherent light with a fluency of 75 J/cm\*2 and fluency rate of 50-200 mW/cm\*2 up to 14 weeks. All participants received two consecutive treatments, one week apart thereby completing one PDT treatment cycle.
An autogenous vaccine e.g. Haemophilus Pleuropneumonia vaccine is obtained by growing bacteria in a liquid culture medium at 37 DEG C for 6 to 48 hours. The bacterial suspension is checked for purity and a sterilisation fluid comprising Thiomersal and Formalin is then added. The suspension is incubated at 37 DEG C for typically 48 hours. After 24 and 48 hours sterility checks are carried out by immersing a swab in the suspension, inoculating a blood agar plate and incubating the plate at 37 DEG C for between 48 hours aerobically. The plates are then examined for sterility. A second sterility check includes inoculating the vaccine into a Thioglycollate broth and soya bean-casein digest media.
OBJECTIVES: Determine comparative tolerance of daily oral and weekly parenteral cobalamin supplementation, in hypocobalaminaemic dogs with chronic enteropathy. Determine whether oral is as effective as parenteral supplementation at achieving eucobalaminaemia, in hypocobalaminaemic dogs with protein-losing enteropathy, severe hypocobalaminaemia or high canine inflammatory bowel disease activity index at inclusion.
MATERIALS AND METHODS: Thirty-seven client-owned dogs with hypocobalaminaemia and clinical signs of chronic enteropathy were prospectively enrolled in three UK referral centres. Dogs were randomly allocated to daily oral for 12 weeks or weekly parenteral cobalamin supplementation for 6 weeks and one additional dose 4 weeks later. Serum cobalamin, body condition score, canine inflammatory bowel disease activity index and bodyweight were assessed at inclusion, weeks 7 and 13. Serum methylmalonic acid concentration was evaluated at inclusion and at week 13. Owners completed treatment adherence, palatability, tolerance and satisfaction questionnaires at week 13.
RESULTS: Nineteen dogs completed the study. All dogs orally supplemented achieved normal or increased cobalaminaemia at weeks 7 and 13. There was no statistical difference in cobalamin concentration at week 13 in dogs treated with oral or parenteral supplementation, regardless of presence of protein-losing enteropathy, severity of hypocobalaminaemia or canine inflammatory bowel disease activity index at inclusion. Serum methylmalonic acid concentration was not significantly different between oral and parenteral groups, neither were treatment adherence, satisfaction, and tolerance scores at week 13.
CLINICAL SIGNIFICANCE: Oral is as effective and as well-tolerated as parenteral cobalamin supplementation in hypocobalaminaemic dogs with chronic enteropathy and severe clinical or biochemical phenotypes, and should be considered as a suitable treatment option regardless of disease severity.
Fibrinogen concentrate (FC) for acquired hypofibrinogenemia associated with critical obstetrical hemorrhage (COH) was covered by public medical insurance in September 2021 in Japan. We aimed to investigate changes in the policy of FC use and its effect on COH after insurance coverage. A primary survey covering September 2020 to August 2021 and a secondary survey covering September 2021 to August 2022 were conducted at 428 higher-level medical facilities. We investigated the policy of FC use in transfusion strategy and the maternal outcomes in COH. Among the hospitals that responded to both surveys, the number of facilities that use FC increased from 51.5 (101/196) to 78.6% (154/196) (P < 0.0001). The number of COH cases treated using FC increased from 14.3 to 24.3% (P < 0.0001) and that transfused with ≥ 10 units of red blood cells (RBCs) decreased from 36.8 to 29.8% (P = 0.001). The incidence of pulmonary edema reduced by 3.7-2.0% (P = 0.021), and transfusion-induced allergy by 1.9-0.7% (P = 0.008). No changes were observed in the incidence of thromboembolism, arterial embolization, or hysterectomy. The increased use of FC after insurance coverage led to changes in the transfusion strategy, which may be associated with decreases in transfusions of RBCs, pulmonary edema, and transfusion-induced allergies.
The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. In this group PEEP was set to 8 cmH2O, after the recruitment maneuver, and was left until the end of the operation.
Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
Subjects will receive two implants for fixation of the distal femur fracture. The dual implant will be either 2 plates with screws or a plate with screws and a rod. The type of dual implant used will be determined by the surgeon based on the characteristics of the fracture.
The VIRDICT study is a randomized, open-label clinical study including participants aged 30-80 years old, who underwent coronary computed tomography angiography (CCTA) and had no obstructive coronary stenoses. CCTA images will be transferred as pseudonymized DICOM data to Caristo Diagnostics Ltd for perivascular fat analysis. Individuals with evidence of coronary inflammation, as assessed by fat attenuation index (FAI) will be eligible for the VIRDICT study. Participants will be randomized either to standard of care treatment or inflammation-based treatment with atorvastatin ± colchicine. Participants will be followed-up for 6 months post randomization, with four follow-up visits (two by telephone call and two by onsite visit). At the end of their follow-up, participants will undergo a second CCTA and the relevant images will be analyzed for pericoronary inflammation. 140 participants are expected be included in the study. Interim analyses will be performed after sufficient patients (approximately 80 patients) have completed 24 weeks of follow-up. This is a pilot study to establish the ability of CCTA-derived FAI quantification to detect a change in coronary artery inflammation, following a period of treatment with medications with known anti-inflammatory properties (statin and colchicine).
Bisphenol S (BPS), a substitute for bisphenol A, is widely used in the manufacture of food packaging materials, raising concern over its toxicity. However, evidence is still lacking on whether gut microbiota involved in BPS induced intestinal inflammation in mammals, as well as its underlying mechanism. Using mouse BPS exposure model, we found intestinal inflammation characterized by shortened colon length, crypt distortion, macrophage accumulation and increased apoptosis. As for gut microbiota, 16s rRNA gene amplicon sequencing showed BPS exposure induced gut dysbiosis, including increased pro-inflammatory microbes such as Ileibacterium, and decreased anti-inflammatory genera such as Lactobacillus, Blautia and Romboutsia. Besides, LC-MS/MS-based untargeted metabolomic analysis indicated BPS impaired both bacteria and host metabolism. Additionally, transcriptome analysis of the intestine revealed abnormal gene expression in intestinal mucosal barrier and inflammation. More importantly, treating mice with antibiotics significantly attenuated BPS-induced gut inflammation via the regulation of both bacterial and host metabolites, indicating the role of gut microbiota. Collectively, BPS exposure induces intestinal inflammation via altering gut microbiota in mouse. This study provides the possibility of madecassic acid, an anti-inflammatory metabolite, to prevent BPS-induced intestinal inflammation and also new insights in understanding host-microbiota interaction in BPS toxicity.
The purpose of the present invention is to change the normal metabolic environment of cancer cells by using artificial diets in which the levels and ratios of lipids and specific amino acids are manipulated. Owing to changes in their DNA, the cancer cells will not be able to fully adapt to the new metabolic environment, which will reduce their survivability and their protection from the immune system. The invention provides artificial diet compositions that induce surprising antineoplastic activities in animal models of metastatic cancers. These activities were above those observed in mice that received the pharmacological treatments used in cancer patients. The invention demonstrates that methionine and leucine levels have a significant impact on the in-vivo antineoplastic activity of the diets. In all the active diets, the methionine levels are less than or equal to 0.6% and the leucine levels are less than or equal to 10% by total weight of the entire dry composition.
Splenic cysts are uncommon and classified into parasitic and non-parasitic origins. Non-parasitic cysts are further categorised into primary and secondary forms; primary cysts develop congenitally and progress into adulthood and secondary cysts result from factors such as abdominal trauma, infection or ischemia. This case series presents three instances of splenic cysts in children. The first case involves a splenic epidermoid cyst, the second a pseudocyst and the third a splenic epithelial cyst. All patients exhibited an abdominal lump in the left quadrant that increased in size over time, without additional symptoms. The third patient had a history of abdominal blunt trauma a year prior to symptom onset. Treatment approaches varied: the first and third patients underwent total splenectomy, while the second patient underwent aspiration drainage with frozen section analysis and partial splenectomy. All patients, first, second and third, were discharged 6, 3 and 5 days postoperatively, respectively, without complications. Splenic epithelial cyst (SEC) emerged as the predominant primary non-parasitic splenic cyst type, with an unclear pathogenesis. Typically asymptomatic, splenic cysts are commonly detected incidentally during imaging or exploratory laparotomy. Histopathology stands as the gold standard diagnostic method for splenic cysts. Although rare, paediatric splenic cysts should be considered in cases of abdominal trauma. Imaging serves a vital role in diagnosis, guiding decisions between conservative or surgical interventions based on cyst size, symptoms and associated complications.
The present invention relates to Acipenser Qiankun decoction for preventing and treating atypical pneumonia, which is prepared to prevent and treat atypical pneumonia popular in a plurality of areas at present. Cotton root, bryozoatum or dry suakwa and dandelion are mainly used, are matched into a No. 1 prescription and a No. 2 prescription by using three kinds of medicines in an auxiliary mode, and are prepared into decoction and granular electuary. The present invention has the functions of strong pathogen resistance, virus resistance, exterior syndrome relief, heat clearness and toxicity removal, cough stop, phlegm elimination and antiasthmatic action. The present invention is used for preventing ' atypical pneumonia' and treating patients with 'atypical pneumonia'. The decoction and the granular electuary prepared by the present invention have the functions of strong pathogen resistance, virus resistance, exterior syndrome relief, heat clearness and toxicity removal, cough stop, phlegm elimination and antiasthmatic action. Through a test, the treatment effect of the decoction and the granular electuary is obvious.